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A caspase-3 ‘death-switch’ in colorectal cancer cells
for induced and synchronous tumor apoptosis in vitro
and in vivo facilitates the development of minimally
invasive cell death biomarkers
KL Simpson1, C Cawthorne2, C Zhou1, CL Hodgkinson1, MJ Walker1,3, F Trapani1, M Kadirvel2, G Brown2, MJ Dawson1,
M MacFarlane4, KJ Williams2, AD Whetton3 and C Dive*,1
Novel anticancer drugs targeting key apoptosis regulators have been developed and are undergoing clinical trials.
Pharmacodynamic biomarkers to define the optimum dose of drug that provokes tumor apoptosis are in demand; acquisition of
longitudinal tumor biopsies is a significant challenge and minimally invasive biomarkers are required. Considering this, we have
developed and validated a preclinical ‘death-switch’ model for the discovery of secreted biomarkers of tumour apoptosis using
in vitro proteomics and in vivo evaluation of the novel imaging probe [18F]ML-10 for non-invasive detection of apoptosis using
positron emission tomography (PET). The ‘death-switch’ is a constitutively active mutant caspase-3 that is robustly induced by
doxycycline to drive synchronous apoptosis in human colorectal cancer cells in vitro or grown as tumor xenografts. Death-
switch induction caused caspase-dependent apoptosis between 3 and 24 hours in vitro and regression of ‘death-switched’
xenografts occurred within 24 h correlating with the percentage of apoptotic cells in tumor and levels of an established cell death
biomarker (cleaved cytokeratin-18) in the blood. We sought to define secreted biomarkers of tumor apoptosis from cultured cells
using Discovery Isobaric Tag proteomics, which may provide candidates to validate in blood. Early after caspase-3 activation,
levels of normally secreted proteins were decreased (e.g. Gelsolin and Midkine) and proteins including CD44 and High Mobility
Group protein B1 (HMGB1) that were released into cell culture media in vitro were also identified in the bloodstream of mice
bearing death-switched tumors. We also exemplify the utility of the death-switch model for the validation of apoptotic imaging
probes using [18F]ML-10, a PET tracer currently in clinical trials. Results showed increased tracer uptake of [18F]ML-10 in
tumours undergoing apoptosis, compared with matched tumour controls imaged in the same animal. Overall, the death-switch
model represents a robust and versatile tool for the discovery and validation of apoptosis biomarkers.
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Evasion of apoptosis is a hallmark of cancer,1 and conse-
quently, re-initiating selective tumor cell death is a principal goal
in anticancer drug development. This may be achieved by
exploiting signalling pathways that control cell survival or initiate
cell death, which are commonly deregulated in tumors.2
Substantial effort is focused on novel agents designed
specifically to activate pro-apoptotic signalling and overcome
the anti-apoptotic molecular ‘roadblocks’ that allow tumor cells
to survive in harsh microenvironments and resist current
therapies.3 Examples include drugs targeted to anti-apoptotic
Bcl-2 family proteins and to inhibitors of apoptosis (IAP)
proteins and activators of the TRAIL death receptor signalling
pathway.2
In parallel to drug development, there is a clear requirement
for biomarkers of tumor cell death applicable during early
clinical trials. The acquisition of tumor tissue pre- and post-
drug treatment is challenging whereas less invasive, serial
blood sampling is commonplace. Similarly, imaging
approaches offer the prospect of the assessment of cell death
non-invasively. Our aim therefore was to develop a robust and
versatile model system to facilitate discovery of novel
biomarkers via these complimentary approaches. In the first
instance, we sought identification of novel pharmacodynamic
biomarkers in vitro that could potentially inform on and
quantify drug-induced apoptosis in the circulation of cancer
patients. It is likely that a ‘tumor cell death signature’ will have
1Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, University of Manchester and Manchester Cancer Research Centre, Wilmslow
Road, Withington, Manchester, UK; 2Wolfson Molecular Imaging Centre, University of Manchester, 27 Palatine Road, Manchester, UK; 3Stem Cell and Leukaemia
Proteomics Laboratory, School of Cancer and Enabling Sciences, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital,
Manchester, UK and 4MRC Toxicology Unit, Hodgkin Building, University of Leicester, Lancaster Road, Leicester, UK
*Corresponding author: C Dive, Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, University of Manchester and
Manchester Cancer Research Centre, Wilmslow Road, Withington, Manchester M20 4BX, UK. Tel: +44 (0)161 446 3036; Fax: +44 (0)161 446 3109;
E-mail: CDive@PICR.man.ac.uk
Received 06.11.12; revised 22.2.13; accepted 25.2.13; Edited by A Stephanou
Keywords: biomarkers; apoptosis; capase-3; death-switch; proteomics; imaging
Abbreviations: cCK18, caspase-cleaved cytokeratin-18; CK18, cytokeratin-18; cC3, cleaved caspase-3; cPARP, cleaved PARP; CRC, colorectal cancer; HMGB1,
High Mobility Group Protein B1; Hsp90, Heat Shock Protein 90; iTRAQ, isobaric tagging for relative and absolute quantification; MALDI-TOF, matrix-assisted laser
desorption ionisation-time of flight; MS, mass spectrometry; PET, positron emission tomography; RPLC, reverse phase liquid chromatography
Citation: Cell Death and Disease (2013) 4, e613; doi:10.1038/cddis.2013.137
& 2013 Macmillan Publishers Limited All rights reserved 2041-4889/13
www.nature.com/cddis
increased power and sensitivity over a single biomarker. The
use of an unbiased global approach may also increase
understanding of the apoptosis process in tumor cells per se.
We also sought to demonstrate proof-of-principle that
our cell death model would have utility for the preclinical
validation of imaging biomarkers of apoptosis that are
translatable to the clinic.
Apoptosis culminates in activation of caspases (initiator
caspases cleave and activate downstream effector cas-
pases), a family of cysteine proteases primarily responsible
for orchestrating the demolition of key cellular structures and
the subsequent engulfment of apoptotic corpses by
phagocytes.4–6 Hundreds of proteins undergo restricted
proteolysis by effector caspases,7 resulting in a myriad of
changes in the proteome. Effector caspase activation is
therefore stringently regulated. The preclinical model devel-
oped here (referred to as the ‘death-switch’) exploits the
convergence of apoptotic signalling pathways on caspase-3
and relies on the tightly controlled, doxycycline-inducible
activation of a constitutively active mutant of caspase-3 (or an
inactive point mutant)8 to drive synchronous apoptosis in
HT29 colorectal cancer (CRC) cells. Here, there is no reliance
upon upstream, potentially confounding signalling events and
apoptosis irrevocably occurs when the active protein is
inducibly expressed. CRC is the third most common
cancer type worldwide according to the GLOBOCAN 2008
Cancer Incidence and Mortality Worldwide Database (http://
globocan.iarc.fr) and thus warrants further study. However,
the death-switch approach is applicable to any readily
transfectable tumour cell line.
Changes in both intracellular and secreted/released pro-
teins after synchronous induction of the death-switch are
measurable both in vitro and in vivo using human tumor
xenograft models allowing correlative assessment of apopto-
sis in the tumor and in the bloodstream. In this study, the
‘death-switch’ model was used in vitro to examine biomarkers
of apoptosis via a mass-spectrometry (MS)-based global
proteomic approach and to demonstrate utility in the
preclinical validation of apoptotic imaging agents using PET
[18F]ML-10, a PET tracer currently undergoing clinical trials in
oncology.9,10
Results
Generation of a HT29 human CRC cell line that
undergoes tightly regulated, rapid and synchronous
apoptosis. To investigate the kinetics of tumor apoptosis
in vivo and the resultant proteomic changes, it was
necessary to generate a model whereby apoptosis induction
was tightly controlled and synchronous. RevC3 and revC3 C/
A constructs8 were subcloned into the pTRE2hyg vector,
which permits their expression only in the presence of
doxycycline (dox). Vectors were transfected into the HT29
CCE9 parental cell line11 in order to generate revC3 (death-
switch) and revC3 C/A (inactive point mutant) clones. Clones
were selected based on expression of revC3 and revC3 C/A
and their ability upon dox exposure to exhibit functional and
morphological characteristics of apoptosis (Figure 1).
Expression was monitored using a caspase-3 antibody
directed towards D175 of the large subunit, normally
exposed only under conditions of endogenous caspase-3
cleavage (and undetectable in the full-length pro-enzyme),
which due to the generation of either revC3 or revC3 C/A due
to subunit rearrangement is present at the C-terminus of
these proteins. RevC3 (Figure 1a(i)) and revC3 C/A
(Figure 1a(ii)) were rapidly and continually induced from 3–
24 h after dox. Overexpression of revC3 generated the p19
large subunit of caspase-3 after 4 h (increased at 6 h) and
cleavage of an established caspase-3 substrate, PARP,
while overexpressed revC3 C/A was catalytically inactive,
confirmed by the absence of PARP cleavage. Although in the
case of revC3 C/A a small amount of the p19 subunit was
detectable after 6 h, this did not generate catalytically active
protein (shown by the lack of cleaved PARP). Furthermore,
PARP cleavage by revC3 (in addition to generation of the
p19 subunit) was inhibited by the pan-caspase inhibitor, Boc-
D-FMK (Figure 1a(i)), indicating a specific caspase-driven
apoptotic effect.
While cells in the absence of revC3 (Figure 1b(i)) or in
presence or absence of revC3 C/A (Figure 1b(ii)) expression
displayed the same growth kinetics in vitro as the parental cell
line, dox induction of revC3 rendered cells non-viable within
24 h (Figure 1b(i)). These data demonstrate that revC3
expression induced a ‘non-leaky’ cell death, indicative of a
robust model system. Expression of the transgene per se is
not detrimental to cells, as shown by revC3 C/A expression.
The functional and morphological characteristics of cells
upon induction of revC3 were consistent with apoptosis, in
comparison to revC3 C/A-expressing cells (Figure 1c).
Caspase activity after 6 h of dox exposure was significantly
higher in revC3 cells compared with revC3 C/A cells
(Po0.001) (Figure 1c(i)) and was quenched by the addition
of caspase-3 inhibitor DEVD, indicating a caspase-3 depen-
dence. After 24 h of caspase activation in revC3 cells,
caspase activity was reduced to baseline, which when
correlated with cell viability (Figure 1c(ii)) was consistent with
B50% of these cells being rendered non-viable (Pp0.03
versus all other groups). After 6 h, 73% of revC3-expressing
cells in the presence of dox exhibited classical nuclear
apoptotic morphology (nuclear condensation/fragmentation)
in comparison to o5% of revC3 cells in the absence of dox
and revC3 C/A cells regardless of dox (Figure 1c(iii)). Taken
together, the data show that induction of the death-switch
provokes rapid, synchronous expression and activation of
caspase-3 and subsequent apoptosis.
Expression of revC3 in tumors leads to rapid, synchro-
nous apoptosis in vivo, which correlates with tumor
regression, tumor apoptosis and circulating levels of
cytokeratin-18. Selective expression of the death-switch or
the inactive point mutant in tumors in vivo was obtained by
dosing tumor-bearing mice with dox by oral gavage every
24 h, after tumors reached a volume of 800mm3.
Tumor growth kinetics are shown in Figure 2a. In the
absence of dox, revC3-containing xenografts (Figure 2a(ii))
displayed the same growth kinetics (not significantly
different: two-way analysis of variance (ANOVA)) as the
revC3 C/A cells, both in the presence and absence of dox
(Figures 2a(iii) and (iv), respectively) throughout the
experiment. Following dox, a marked tumor regression
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occurred in revC3 xenografts by 24 h (Figure 2a(i)), with
tumor shrinkage to B50% of original size by 48 h dox (two-
way ANOVA followed by Student–Neuman–Keuls test,
Po0.001; Figure 2a(v)).
In revC3 xenografts, there were substantial increases in the
number of cells that stained positively for all three apoptotic
biomarkers (Figure 2b(i), quantitated in (ii)) (cPARP, 54.8%,
Po0.001; cC3, 20.9%, Po0.001; caspase-cleaved CK18
(cCK18), 21.6%, Po0.02; revC3þ dox versus all other
groups). Differences in the proportion of cells that stained
positive for each marker may be attributed to the quality of the
antibody, in combination with the timing of the sample; for
example, cC3 may appear earlier and be more rapidly
degraded than cPARP. There was a maximum of 11%
apoptotic cells in tumors (cCK18) either not exposed to dox
or where the inactive point mutant replaced RevC3
(Figure 2b(ii)). Significant differences were observed in tumor
volume and cPARP as early as 3 h post dox (compared with
mice not receiving dox), whereas cC3 levels were significantly
increased by 8 h and cCK18 by 24 h (Po0.02 in all cases)
(Figure 2b(iii)).
The M65 ELISA measures levels of human full-length and
caspase-cleaved CK18 (cCK18), giving an indication of the
amount of total cell death occurring in epithelial cells,12 while
the M30 ELISA measures the levels of cCK18 only and thus
reports epithelial cell apoptosis.13,14 These ELISAS have poor
affinity for mouse CK18. In agreement with tumor biomarker
data (Figure 2b), circulating CK18 in revC3 xenografts 24 h
after dox was significantly elevated compared with all other
groups and also correlated with tumor regression (Po0.01)
Figure 2c(i). Furthermore, the agreement between M65 and
M30 data inferred that the predominant mode of induced cell
death was apoptosis. While tumor volumes were significantly
decreased from 3h compared with tumors prior to dox
(Po0.01), M30/M65 levels became significantly elevated
from 8h (Po0.01) (Figure 2c(ii)). Together, these data
validate the death-switch model as a robust in vivo model of
regulated, synchronous apoptosis and with the kinetics of
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Figure 1 Validation of the death-switch in vitro. (a) Levels of revC3, endogenous cleaved caspase-3, p19 large subunit of cleaved caspase-3 and PARP in revC3-
expressing± Boc-D-FMK (1mM) (i) or revC3 C/A (ii) cells± dox, for 3, 4, 6 or 24 h. Lysates were probed for expression and processing as an indicator of apoptosis. Loading
controls are actin and tubulin. Data shown are representative of three independent experiments. The large p19 subunit of caspase-3 (generated by cleavage of the
pro-enzyme) is denoted by ‘p19’. (b) Cell population growth kinetics of revC3 and parental HT29 CCE9 cells (i) and revC3 C/A and parental HT29 CCE9 (ii) cells± dox daily
for 7 days. (i) RevC3þ dox (K), revC3 dox (’), HT29 CCE9þ dox (m), HT29 CCE9 dox (~). (ii) revC3 C/Aþ dox (K), revC3 C/A dox (’), HT29 CCE9þ dox
(m), HT29 CCE9 dox (~). Data shown are the mean of n¼ 3±SD. (c) Kinetics of caspase-3 activity by fluorometric caspase-3 assay of revC3- and revC3 C/A-expressing
cells± dox,±DEVD-CHO (i). (ii) Changes in cell viability in revC3- versus revC3 C/A-expressing cells± dox. (iii) Nuclear morphology of revC3 and revC3 C/A cells± dox
for 6 h, % number of cells with apoptotic nuclear morphology. Solid black bars,þ dox; open white bars, dox; light grey bars,þ dox,þDEVD-CHO; hashed bars,
 dox,þDEVD-CHO. Data shown are mean of n¼ 3±SEM. **Po0.001 versus C/A 6 h. *Po0.003 versus all other groups
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tumour cell death in vitro and in vivomapped, we then sought
to demonstrate the utility of this model for biomarker discovery
and validation using the complimentary approaches of
proteomics and imaging.
Design and implementation of a proteomic workflow to
assess early changes in the secretome of tumor cells
triggered to undergo apoptosis. We recently developed a
gel-free, proteomic workflow for relative quantification of
proteins using iTRAQ labelling and tandem MS for analysis
of samples such as conditioned media or plasma/serum
(Figure 3a).15 Figure 3b outlines the experimental design
using this method, where changes in the identities and
relative levels (up and down) of proteins secreted/released
into the media of ‘death-switched’ cells after 6, 8 and
24 h were profiled as potential tumor death biomarkers.
ProteinPilot identified 25714 peptides. A q-value threshold of
confidence 40.29 (see Supplementary Material and 15) was
applied resulting in 4657 peptides amongst which, 650 had
reliable iTRAQ labelling. These peptides originated from 121
non-redundant proteins (identified with X2 peptides,
Supplementary Table 1). The protein false discovery rate
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Figure 2 Validation of the death-switch in vivo. (a) Changes in tumor volume± dox for individual SCID/bgmice bearing RevC3 or C/A xenografts (i–iv). (i) RevC3-bearing
animalsþ dox gavage, (ii) RevC3-bearing animalsþ control (water) gavage, (iii) C/A-bearing animalsþ dox gavage, (iv) C/A-bearing animalsþ control (water) gavage. Each
line represents a single animal from time of implant to point of sacrifice. When tumours reachedB800mm3, animals were given dox (daily gavage 0.2 mg/ml p.o) or water,
represented by a dotted horizontal line. (v) Data from (i–iv) represented as mean±SEM (***Po0.001); solid black bars, revC3þ dox; open white bars, revC3 dox; light
grey bars, C/Aþ dox; hashed bars, C/A dox; n¼ 7–10 animals per group. (b) Representative images of staining for cleaved caspase-3, cleaved PARP and caspase-
cleaved CK18 as tissue biomarkers of apoptosis in RevC3 and C/A xenografts 24 h± dox (i). Quantitation of these data in comparison to the parental cell line (par) and
tumour volumes (ii). Kinetics of revC3 tumor apoptosis in comparison to tumor volumes (iii): black line, tumor volume, solid black bars, cleaved caspase-3, open white bars,
cleaved PARP, grey bars, caspase-cleaved CK18. Error bars represent±SEM, 2–4 mice per group, 2–5 sections per group, *Po0.02, 2 independent counts. (c) Correlation
of circulating CK18 levels with tumor volumes (black line) in parental, revC3 and C/A xenograft-bearing mice (i). Kinetics of these changes in revC3 following dox (ii). Grey bars,
total CK18; open white bars, caspase-cleaved CK18. Data shown are mean±SEM, 2–4 mice per group, **Po0.01
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(FDR) was 3.36%, thus protein identifications were deemed
valid. Peptide and protein level variances are displayed in
Supplementary Figure 1.
Technical variance was within acceptable limits of log2
0.85–1.27 ( 0.24 to þ 0.34 after log2 transformation).
Differentially expressed/present proteins following apoptosis
induction were defined by boundaries representing 95%
confidence intervals (CI) by assessment of variance between
biological replicates at three different time-points. The upper
and lower boundaries of CI were log2 0.65–1.49 ( 0.62 to
þ 0.57 after log2 transformation), resulting in 57/121 proteins
present inmedia from cells at significantly altered levels at one
or more time-points compared with non-apoptotic cells
(Supplementary Figure 1, Table 1). Several of these were
caspase substrates (Table 1, italic type), see Discussion. Of
particular interest were fold changes occurring at early time-
points (6 and 8 h); as during this period, 490% cells
maintained plasma membrane integrity, although 470%
demonstrated apoptotic nuclear morphology (Figures 1c (ii)
and (iii), respectively). Differentially expressed proteins were
grouped according to their normal subcellular localisation
(http://www.uniprot.org/) (Table 1). Proteins were defined as
secreted (17 proteins, 30% total differentially expressed),
membrane-bound (11 proteins, 19% total), cytoplasmic
(13 proteins, 23% total), nuclear (11 proteins, 19% total), or
of unspecified location (5 proteins, 9% total). The secreted
proteins group was the largest, although all subcellular
localisations were well represented.
Global protein increases and decreaseswere detected at all
three time-points; interestingly, levels of secreted proteins all
decreased and the majority of these (14/17) decreased at 6 h
and remained so throughout the time course. In contrast,
cytoplasmic proteins were found to be generally increased in
the cell media (Table 1). Nuclear proteins were both increased
and decreased and with the exception of HMGB1, HNRPA2
and Plasminogen Activator Inhibitor 1 RNA-binding Protein
(elevated at 6 hour), the majority of changes occurred at 24 h.
It must be noted that although CK18 was detected by the
proteomics screen, it was not differentially expressed (see
Discussion).
Several candidates were chosen for further validation, and
western blotting for HMGB1, Heat Shock Protein 90 (Hsp90)
and Nucleolin confirmed these increases, with Cytokeratin-8
as a loading control (detected in the proteomic screen with
unchanged levels throughout) (Supplementary Table 1)
(Figure 4a). Upregulation of CD44 was verified by ELISA (as
western blotting was confounded due to the many splice
variants of this protein) (Figure 4b). In agreement with
proteomic data (Table 1), CD44 levels were significantly
increased 24 h after induction of the death-switch (t-test,
Po0.05). These data indicate that the proteomics method
adopted here is valid for biomarker discovery with demon-
strable agreement for protein expression changes between
different methodologies.
Analysis of tumor and plasma from mice bearing
‘death-switched’ tumors for novel circulating biomar-
kers of apoptotic tumor cell death. The results generated
by the in vitro proteomics screen were also corroborated in
the plasma of mice bearing ‘death-switched’ tumors and as
such could represent potential novel circulating biomarkers
of apoptosis with demonstrable translational relevance.
Substantially increased levels of HMGB1 were found in the
plasma of these animals at 24 and 48 h (Figure 4c(i)).
Furthermore, soluble CD44 was also increased at these
time-points (Figure 4b(ii)). Early changes in HMGB1
observed in the proteomics screen were not found in vivo
and it is possible that this reflects the more complex kinetics
of release into the bloodstream in vivo. Interestingly,
Figure 4c(i) appears to show several different isoforms of
HMGB1, with at least two forms detectable in uninduced and
24- and 48-h post-dox time-points and possible other forms
of intermediate size in the other time-points. This is in
comparison to the single form of HMGB1 seen in the cell
culture supernatant (Figure 4a). In order to investigate this
further, HMGB1 in plasma from mice bearing death-switch
tumours (or non-tumor bearing controls) was analysed by
Nanofluidic proteomic immunoassay using the NanoPro1000
(ProteinSimple, Santa Clara, CA, USA). This technique
separates native state proteins by isoelectric point before
antibody detection. The signal from each time-point was
subtracted from the background reading obtained from over
the time course (Figure 4c(ii)). A more acidic form was
present in the uninduced tumours (pI 4.6), which reduced to
low levels at 24 h, at which point a less-acidic form (pI 6.5)
could be detected, only present at 24 h. It is possible that this
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Figure 3 Proteomic workflow and experimental design to investigate apoptosis-
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labelling and MS/MS mass spectrometry. (b) Experimental design to investigate
proteomic changes in the cell culture supernatant of ‘death-switched’ cells. Numbers
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Table 1 Proteins secreted into cell culture media with significant fold changes following induction of the death-switch after 6, 8 and 24 h
Protein Name Fold change at each time-point post dox (log2)
6 h 8 h 24 h
Secreted proteins
AGRN Agrin 1.41  1.40  1.92
B2M Beta-2-microglobulin 1.634  1.66  2.50
CST3 Cystatin-C 1.57  1.60  2.34
GRN Granulins 0.98  1.07  2.16
GSN Gelsolin 1.14  1.02  1.74
HSPG2 Basement membrane-specific heparan sulfate proteoglycan core protein 1.51  1.52  2.53
KLK6 Kallikrein-6 0.90  1.04  2.03
LGALS3BP Galectin-3-binding protein 1.03  1.12  1.21
THBS1 Thrombospondin-1 1.06  1.03  1.61
TWSG1 Twisted gastrulation protein homolog 1 0.99  0.88  1.85
SERPINA1 Alpha-1-antitrypsin 1.43  1.23  2.06
LRG1 Leucine-rich alpha-2-glycoprotein 0.650 1.00  1.36
LYZ Lysozyme C 1.44  1.71  1.80
SPINT1 Kunitz-type protease inhibitor 1 0.14  0.08  0.58
HP Haptoglobin 0.16 0.20  0.91
AMY1B Alpha-amylase 1 0.38 0.22  1.20
MDK Midkine 1.31  1.26  1.89
Membrane proteins
ADAM17 Disintegrin and metalloproteinase domain-containing protein 17 0.41  0.83  1.39
LSR Lipolysis-stimulated lipoprotein receptor 1.08  1.08  1.99
SDC4 Syndecan-4 0.58  0.74  1.36
SPINT2 Kunitz-type protease inhibitor 2 0.49  0.39  0.71
SHISA5 Protein shisa-5 1.73  1.71  2.91
EFNB1 Ephrin-B1 0.33 0.82  0.07
ST14 Suppressor of tumorigenicity protein 14 0.09 0.31 1.15
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 0.29  0.06 1.17
*CD44 CD44 antigen 0.44 0.41 0.82
DSG2 Desmoglein-2 0.00 0.66 0.48
BCAM basal cell adhesion molecule precursor 0.08 0.64 0.82
Cytoplasmic proteins
CTSH Cathepsin H 0.72  1.27  2.56
HNRNPA2B1 Heterogeneous nuclear ribonucleoprotein 2B1 0.60 0.09  0.32
TUBA1B Tubulin-a-1B 0.61 0.47 0.26
TMOD2 neuronal tropomodulin 0.66 0.77 0.07
S100A11 Protein S100-A11 0.33 0.07  0.98
SERBP1 Plasminogen activator inhibitor 1 RNA-binding protein 0.65 0.21 0.18
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 0.29  0.06 1.17
*HSP90 heat shock 90kDa protein 0.26 0.21 0.64
*NCL Nucleolin 0.10  0.03 1.16
PFN1 Profilin-1 0.17  0.39 0.65
PGK1 Phosphoglycerate kinase 1 0.25  0.08 0.78
PKM2 Pyruvate kinase isozymes M1/M2 0.13 0.11 0.82
SET Protein SET 0.44 0.33 2.27
Nuclear proteins
HIST1H1B Histone H1.5 0.10 0.12  1.16
HIST1H1D Histone H1.3 0.21 0.16  0.98
HIST1H1E Histone H1.4 0.07 0.02  0.91
HIST1H2BN Histone H2B type 1-N 0.27 0.23  1.13
HNRNPA2B1 Heterogeneous nuclear ribonucleoprotein 2B1 0.60 0.09  0.32
SERBP1 Plasminogen activator inhibitor 1 RNA-binding protein 0.65 0.21 0.18
S100A11 Protein S100-A11 0.33 0.07  0.98
*HMGB1 High mobility group protein B1 0.66 0.39 0.89
*NCL Nucleolin 0.10  0.03 1.16
PKM2 Pyruvate kinase isozymes M1/M2 0.13 0.11 0.82
SET Protein SET 0.44 0.33 2.27
Proteins with unspecified location
ATIC Bifunctional purine biosynthesis protein PURH 0.62 0.56 0.22
SPINK5 Serine peptidase inhibitor 0.82  0.69  1.77
MDH2 Malate dehydrogenase 0.04  0.06  0.96
EEF1D Eukaryotic translation elongation factor 1 delta 0.23  0.02 0.67
TUBB3 Tubulin-b3 0.80 0.61 0.79
Proteins identified in the in vitro proteomic screen with differential expression levels in serum-free media after death-switch induction, grouped by subcellular
localization. Fold changes (compared with uninduced cells at 24 h) are expressed as log2 values. Numbers that represent significant fold changes are in bold lype.
Proteins that were verified by alternative methods are in bold type and prefixed by an asterisk (HMGB1, Hsp90, CD44 and Nucleolin). Proteins in the CASBAH
database7 are highlighted in italics (gelsolin, tubulin a-1-B, Hsp90, nucleolin, SET and eukaryotic elongation initiation factor 1 delta).
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second form is the source of the increased levels of HMGB1
observed in the western blot (Figure 4c(i)).
IHC analysis of HMGB1 was undertaken on the xenograft
sections (Figure 4(iii)) and while there were no significant
changes in nuclear HMGB1 expression (data not shown),
analysis revealed significant changes in the expression of
cytoplasmic HMGB1 post death-switch induction (P¼ 0.032,
one-way ANOVA). Under the ANOVA framework, a statisti-
cally significant linear trend over time was also observed
(P¼ 0.003) (Figure 4c(iv).
Validation of [18F]ML-10, an apoptotic imaging agent,
using the death-switch tumour model. To demonstrate
the use of the death-switch model for imaging biomarker
validation, death-switch and control tumours were imaged
before and after induction of revC3 with [18F] ML-10, the first
PET apoptosis imaging agent to reach phase I/II clinical trials
for the detection of cell death.9 There was a significant
increase in [18F] ML-10 uptake (NUVmean) at 24 h post
therapy (2.61±0.69 versus 1.40±0.27, Po0.05), which was
not seen in the control group (2.19±0.68 versus 1.77±0.51)
(Figures 5a–c); expression levels of cC3 and cPARP relative
to actin were also increased as were circulating levels of M30
(data not shown). There was no significant difference in
NUVmean between groups at baseline.
Discussion
In the era of molecularly targeted agents for cancer therapy,
the need for biomarkers to monitor drug-induced changes in
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Figure 4 Verification of proteins that change in media of ‘death-switched’ cells, and in plasma of mice bearing ‘death-switched’ tumors. Cell media was examined before
and after 4, 6, 8 and 24 h induction of revC3. Mouse plasma was evaluated from mice with revC3 xenografts, pre- and up to 24 h post induction of activated caspase-3.
(a) Representative blots for HMGB1, Hsp90 and Nucleolin levels released into media with CK8 as a loading control (15mg total protein was loaded per lane). (b) CD44 (ELISA
for total soluble CD44) released into cell media (i), n¼ 2, mean±SD. *Po0.05 versus minus dox sample and mouse blood (ii) (plasma was pooled from 2–7 mice).
(c) Representative blot for HMGB1 levels in mouse plasma with Ceruloplasmin as a loading control (i). Native protein isoelectric focusing of HMGB1 released into mouse
plasma, n¼ 3, mean±SD (plasma pooled from 2–7 mice) (ii). Representative images of staining for HMGB1 in death-switch xenografts over time (iii). Graphical
representation of levels (%) of cytoplasmic HMGB1 staining from IHC of HMGB1 in xenografts from mice bearing death-switch tumors over time (iv), 2–4 mice per group, one-
way ANOVA (P¼ 0.032, trend analysis P¼ 0.003) black bars, HMGB1 pH 4–5; open white bars, pH 6.45–6.5
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tumors is clear. To this end, we developed and validated an
inducible caspase-3 tumor ‘death-switch’ model, whereby
human cancer cells undergo synchronous apoptosis in vitro
and in vivo (Figures 1 and 2). The model avoids potentially
confounding effects of alternative cell death mechanisms and
non-synchronous kinetics of drug-induced cell death. It
therefore provides an unique opportunity to identify cell death
biomarkers of potential clinical relevance and facilitates
examination of early changes in the microenvironment of
cells destined to die.
Firstly, we demonstrated the use of this model for the
identification of novel biomarkers by a proteomic study of cell
culture media of death-switched cells. The proteomics plat-
form we describe enabled identification of 57 proteins whose
levels change in the media of cells undergoing apoptosis.
Confirmed increases in the cell supernatant of HMGB1,
Hsp90 and Nucleolin were shown by western blotting and
increases in CD44 by ELISA (Figure 4a). CD44 (Figure 4b)
and HMGB1 (Figures 4a and c) also increased in the
bloodstream of mice bearing death-switched tumors and
serve to validate our proteomics approach. In the proteomics
screen, HMGB1 was increased at early (before loss of
membrane integrity) and late time-points and its role in the
dying cell microenvironment may differ depending on the
kinetics of its release. Hyperacetylated HMGB1 is associated
with inflammatory responses,16–18 and it is conceivable that a
tumor cell destined for apoptosis might contribute to triggering
the immune response. This hypothesis is being tested
using a murine cell line engineered to express the death-
switch, grown as a tumor in immune-competent mice.19
In addition to showing that this model is amenable to other
cell lines, this study also showed HMGB1 and Hsp90
release and indicated their potential role as ‘danger signal’
molecules following apoptosis induction. Interestingly,
Kroemer et al.20 have previously shown that release of
HMGB1 from tumor cells undergoing chemotherapy-induced
cell death enhances immunogenic clearance. Hypoacetylated
HMGB1 is released passively during necrosis, thus tumor
cells undergoing synchronous ‘death-switched’ apoptosis
at 24 h may have overwhelmed phagocytic clearance
generating ‘secondary’ necrosis. Hyperacetylated HMGB1
has been shown to be redirected from the nucleus to
the cytoplasm, for eventual secretion via exocytosis,21 and
Figures 4c (iii) and (iv) shows increased expression of
cytoplasmic HMGB1 does indeed increase significantly
following activation of apoptosis in vivo (one-way ANOVA
P¼ 0.032, trend analysis P¼ 0.003). Furthermore, at least
two forms of soluble HMGB1 are present in mouse plasma
following death-switch activation Figure 4c(ii), with a less
acidic form being present only at the 24 h time-point, which
suggests that different post-translational modifications are
present depending upon the degree of apoptosis and/or
necrosis that is present.
CD44 levels were elevated in the plasma of mice bearing
death-switched xenografts at 24–48 h. CD44 is a class I
transmembrane glycoprotein that can act as a receptor for
extracellular matrix components, and is a downstream target
of the Wnt/b-catenin pathway.22 CD44 has been identified as
a colorectal cancer stem cell marker and has been linked with
more aggressive tumours.23
This study also prompted the hypothesis that changes in
released/secreted proteins from cells during the early stages
of apoptosismight not be inconsequential. At early time-points,
Figure 5 Uptake of the apoptotic PET tracer [18F]ML-10 increases in ‘death-
switch’ versus control tumours. Average maximum normalized uptake time activity
curves for revC3 xenografts at baseline (closed symbol) and after 24 h treatment
with doxycycline (open symbol) (average±SEM, *Po0.05) (a) Average maximum
normalized uptake time activity curves for C/A xenografts at baseline (closed
symbol) and after 24 h treatment with doxycycline (open symbol) (average±SEM.)
(b) Maximum intensity projections from summed 30–35min PET data showing
uptake of [18F]ML-10 in revC3 (circled) and C/A xenografts in a representative
animal at baseline and 24 h after doxycycline treatment (c)
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although cells are destined to die, plasma membrane integrity
was maintained (Figure 1c), which may indicate protein
changes that occur in an orchestrated rather than passive
manner and that intracellular events during apoptosis may
direct secretion of specific proteins that have an impact on the
behaviour of surrounding viable cells. There is evidence that
caspase-mediated cellular demolition is not indiscriminate and
effector caspases selectively cleave components of biochem-
ical pathways critical for cell viability.7,24,25
Several proteins whose expression changed in themedia of
death-switched cells in vitro (Figure 3 and Table 1) were
present in the caspase substrate database, CASBAH7
(Table 1, proteins in italic type). Two of these bona fide
caspase substrates, Hsp90 and Nucleolin, have verified
caspase-cleavage sites and were also found to be increased
in media 24 h after death-switch induction. Both were
detectable by western blot in the media of these cells, with
apparent peaks at 24 h, concurrent with proteomics data
(Figure 4a and Table 1), although Hsp90 was detected by
western blot as early as 6 h post death-switch induction.
Extracellular Hsp90 is linked to immune stimulation,26 while
Nucleolin acts as macrophage receptor for apoptotic cells,27
thus potentially explaining its increased expression during
apoptosis induced by the death-switch.
The majority of proteins decreased in the media of death-
switched cells and for many this occurred early (from 6h)
(Table 1). Some of these proteins are associated with
apoptosis and tumorigenesis (e.g. leucine-rich a-2 glycopro-
tein and thrombospondin-1),28,29 but many are not
and are potential novel biomarkers of cell death warranting
further characterisation. Furthermore, decreases in levels of
these secreted proteins did not appear to correlate with
protein half-life, suggesting an ‘orchestrated’ role in cellular
responses to apoptotic cell death. While CK18 was identified
by the proteomics screen at all time-points, somewhat
unexpectedly, its levels were not found to change signifi-
cantly. This can be explained by the greater sensitivity of
ELISA/antibody-based methods compared with the mass
spec approach used here.30 While the iTRAQ method has
many advantages as a global discovery approach,31 it is
limited by underestimation of fold changes.32 Additionally,
both these methods do not provide absolute quantitation, and
thus, CK18 may be below the limit of detection of this mass
spec method.
Secondly, we established the utility of this model for the
validation of apoptosis imaging biomarkers using [18F]ML-10,
a PET tracer. Existing in vivomodels of apoptosis include the
induction of hepatocytic cell death by systemic administration
of drugs, or the treatment of sensitive tumor xenograft models
with chemo- or radiotherapy,33 but these suffer from both
the severity of the procedure to the host animal, as well as the
inherent variability of apoptotic response to stimuli. The
synchronous and well-tolerated induction of cell death in this
model is helpful for the validation of PET imaging biomarkers
in vivo, as this variability is reduced; it also allows the
comparison of longitudinal changes in tracer uptake in tumors
undergoing cell death with control tumors in the same animal,
where the pharmacokinetics of tracer delivery are identical.
Our results show increased uptake of [18F]ML-10 in tumors
undergoing apoptosis as previously reported in vitro34 and in
other apoptotic models in vivo;35 although the overall level
was not as pronounced as reported for the related compound
ML-9 in vivo.36
In summary, the need for non-invasive biomarkers for
clinical use is clear. In the era of novel targeted therapies to
promote tumour apoptosis for the treatment of cancer, the
need for accurate, robust and controllable model systems to
test these drugs and modalities is also evident. Our preclinical
death-switch model allows tightly controlled induction of
apoptosis in vivo with demonstrable application for the
discovery and validation of biomarkers of cell death.
Materials and Methods
Molecular biology. The cDNAs encoding revC3 and revC3 containing a C to
A point mutation within the active site (revC3 C/A)8 were inserted into the multiple
cloning site of pTRE2hyg (Clontech, Laboratories Inc., Mountain View, CA, USA)
to generate pTREhygRevC3 and pTRE2hygRevC3 C/A.
Cell culture. HT29 CCE9 cells were cultured as described previously.11 To
generate revC3 and C/A clones, cells were electroporated with 20 mg
pTRE2hygRevC3 or pTRE2hygRevC3 C/A, respectively and cultured in the
presence of 500mg/ml hygromycin (Sigma, Sigma-Aldrich Ltd., Gillingham, UK) in
10 cm2 dishes for B2 weeks andB100 discrete colonies picked when visible.37
RevC3 and revC3 C/A expression was induced with 2 mg/ml doxycycline (dox)
(Clontech) and clones were screened for revC3 and revC3 C/A expression and
activity by western blotting and for viability by trypan blue exclusion.
Cell viability assays. The sulforhodamine B (SRB) assay was used to
determine cell population number ± 2mg/ml dox.38 Cells were plated in
exponential growth phase in 96-well plates± dox and at daily intervals for 7 days
cells prior to SRB assay. Viability assays was assessed by standard trypan blue
dye exclusion.
Fluorometric caspase-3 activity assay. Cells were seeded in six-well
plates at 1 106 cells/well and 24 h later, cells were incubated ± dox before
harvesting after 2, 6 and 24 h. Cell pellets were resuspended in Caspase-3 Buffer
± Caspase-3 Substrate II DEVD-AMC,± Caspase Inhibitor DEVD-CHO (10mM
stock in DMSO) (R&D Systems, Abingdon, UK).39 Enzyme activity was determined
after 45min at 505 nm (emission) on a Fluostar Optima fluorescence plate reader
(BMG Labtechnologies, Aylesbury, UK). All data were corrected for cell number.
Microscopy. Nuclear apoptotic morphology was assessed by fluorescence
microscopy of fixed cells stained with DAPI.40
Tumor xenografts. RevC3, revC3 C/A and parental cell xenografts were
grown by s.c injection of 1 107 cells (0.1ml of serum-free medium) into the back
mid-dorsal region of 6–8-week-old SCID/bg mice, either a single or dual flank
(different cell lines injected on opposite flanks) model (Paterson Institute for
Cancer Research). For growth and cell death kinetics, the study mice were housed
and tumor size monitored, as previously described,40 until 800 mm3 at which point,
tail vein bleeds were taken. Animals received either dox or water by gavage
(0.2 ml p.o, 10mg/ml) every 24 h for 5 days or until tumors reached 1250mm3,
whichever occurred sooner. On sacrifice or bleeding, blood was collected into
heparinised tubes and plasma was prepared.41 For cell death kinetics studies,
mice were randomised when tumors reached B800mm3 and pre-dox tail vein
bleeds were taken. At various time-points, mice were culled, and bloods and
tumors collected.40 For imaging studies, mice were implanted as previously
described using a dual flank model, and after 17 days animals were selected for
imaging based on having paired size-matched tumours of 300mm3 (within 25%)
before receiving one dose of dox prepared as described above. All procedures
were carried out in accordance with the Scientific Procedures Act 1986 and
UKCCCR Guidelines 2010 by approved protocols following institutional guidelines
(Home Office Project Licence 40-3306 held by Professor C Dive).
Immunohistochemistry. IHC for cleaved caspase-3, cleaved PARP and
caspase-cleaved CK18 was carried out as previously described,42 using the
following primary antibodies: cleaved caspase-3 (Cell Signaling Technology,
Danvers, MA, USA Asp175, product number 9661 1 : 200 dilution), cleaved PARP
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(BD Pharmingen, Oxford, UK Asp214, product number 51-9000017 1 : 100
dilution), M30 (Peviva Bromma, Sweden product number 10700 1 : 100 dilution)
and HMGB1 (AbCam, Cambridge, UK, product number ab18256 1 : 100 dilution).
Control tissue was MDA-231 XG4 breast carcinoma cells43± 1 mM staurosporin.
The negative control rabbit IgG was as follows: cleaved caspase-3, 1 : 25000
(DakoCytomation, Glostrup, Denmark, product number X0936), cleaved PARP,
1 : 20 (DakoCytomation, product number X0931), M30, 1 : 100 (DakoCytomation,
product number X0944). Staining was quantitated as follows: digital images of
whole-tissue sections were acquired using a Leica SCN400 histology scanner
(Leica Microsystems, Milton Keynes, UK). Ten images from each slide were
selected at random at  20 magnification using Mirax Viewer software. The total
number of cells per area was determined using the ‘nucleus counter’ plug-in for
ImageJ software and the number of positive cells per section was counted by two
blinded, independent counters before averaging the data. In the case of HMGB1,
5mm-thick formalin-fixed paraffin-embedded sections were dried for 1 h in a 60 1C
oven. Staining was performed using the BondMax autostainer and reagents
(Leica Microsystems). Deparaffinization was performed automatically in the
autostainer with BondDewax solution at 72 1C for 30min followed by 3 rinses in
each of reagent alcohol and BondWash solution. Slides were then incubated with
Epitope Retrieval Solution 1 (Leica Microsystems, Wetzlar, Germany) for 20min at
100 1C, peroxide block for 5 min. IHC was performed using a pAB against HMGM1
(1 : 200, 18256, Abcam). Antigen was visualized using the EnVision kit (Dako,
Glostrup, Denmark) for 60min. Positive controls included in each run were tonsil
sections positive for HMGB1. Negative controls for each tissue section were
treated the same as test slides with RIgG antibody, dilution 1 : 1000. Images were
analysed using Definiens Developer XD version 2.0.4 and the Tissue Studio Portal
version 3.51 (Definiens AG, Munich, Germany). Regions of interest (ROIs) within
the tissue sections were first identified using Definiens Tissue Studio via machine
learning technology across several samples so that the full range of contrast was
defined. Within these ROIs, nuclei were detected and classified as positive or
negative based on haematoxylin and HMGB1 staining thresholds. Cells were
subsequently simulated around all nuclei and classified as positive or negative
based on thresholds set for the HMGB1 stain within the cytoplasm. All thresholds
remained consistent across tissue sections. For all IHC, 2–4 animals were used at
each time-point. One-way analysis of variance (ANOVA) was applied to HMGB1
staining in xenograft sections, including linear trend analysis under the ANOVA
framework (SPSS Software).
Western blotting. Western blotting was performed, as previously described,40
using the following antibodies: cleaved caspase-3 (Cell Signaling Technology
Asp175, product number 9661, 1 : 100 dilution) and PARP (Cell Signaling
Technology, product number 9542, 1 : 1000 dilution), tubulin (Abcam, product
number ab4074, 1 : 3000 dilution), actin (Sigma, product number a3853, 1 : 2500
dilution), HMGB1 (Abcam, product number ab18256, 1 : 1000 dilution), Cytokeratin-8
(Sigma, product number C5301 1:100 dilution), Ceruloplasmin (Sigma, product
number GW20074F, 1 : 500 dilution), Hsp90 (Enzo Life Sciences, product number
ADI-SPA-846-D, 1 : 1000 dilution) and Nucleolin (AbCam, product number ab13541,
1 : 1000 dilution). In the case of cell culture supernatants, 12% SDS-PAGE gels
were used, while 4–12% gradient gels (Invitrogen, Paisley, UK) were used for the
mouse plasma.
M30/M65 ELISA. ELISA assay for relative quantitation of soluble intact CK18
(M65) and caspase-cleaved CK18 (M30) was carried out on cell culture
supernatant according to the manufacturer’s instructions (Peviva). In the case of
mouse plasma 4 ml Heterophillic Blocking Reagent (HBR Plus, Scantibodies
Laboratory, Inc., Santee, CA, USA) was added to each well and assays were
carried out as previously described.41
CD44 ELISA. ELISA assay for quantitative determination of soluble CD44 in
serum, plasma, buffered solutions and cell culture supernatant (Abcam, Cat
#45912) was carried out according to the manufacturer’s instructions.
Nanofluidic proteomic immunoassay. The total protein concentration
of plasma from SCID/bg mice bearing xenografts of revC3 at 800mm3 (minus dox)
or following dox (2, 4, 6, 8 and 24 h) or non-tumour-bearing control mice (SCID/bg)
was determined using a Bradford assay (Biorad, Hercules, CA, USA). Protein
concentration was then normalised to 2mg/ml using water. In all the following
procedures, sample reagents were from Protein Simple unless otherwise stated.
One microlitre of the mixture was diluted to 200 ng/ml with sample diluent
containing 2% DMSO inhibitor mix. The sample was then further diluted with 30 ml
of Premix G2 pH 5–8 (nested) separation gradient containing pI standard ladder 1.
Four hundred nanolitres of this mix was then separated by isoelectric point using
the NanoPro1000 (Protein Simple) using the power 1 step separation profile, 100 s
immobilisation exposure and 480min primary incubation. HMGB1 antibody
(AbCam, product number ab18256) was used at 1 : 100 dilution. Data were initially
analysed using the NanoPro1000 software, Compass version 1.81, to extract the
raw spectra from the two pI regions 4–5 and 6.45–6.55 as a text. These regions
were selected based on their specificity when compared with non-tumour bearing
control mice. MedCalc (version 12.3.0.0; Ostend, Belgium) was then used to
calculate the area under the curve for each of the samples over the two pI regions.
All analysis was carried out in triplicate, and averages and SD are shown.
Experimental design for proteomics experiments. An overview of
the complete workflow is shown in Figure 3a.
Cell growth and media preparation for proteomics. 1 106 revC3
cells were seeded into T25 flasks (described above), after 24 h culture medium was
removed and cells were washed before incubation with McCoy’s 5A medium minus
fetal bovine serum. After 6, 8 and 24 hþ dox, medium from duplicate flasks was
removed (to provide biological replicates) and after 24 h media from an additional
flask minus dox was also harvested. This sample was split, creating two technical
replicates and processed independently to allow for experimental variability to be
assessed. Cellular debris were removed by centrifuging (500 g, 5min) and
samples stored at  80 1C. Samples were concentrated (B1mg/ml final) and buffer
exchanged into 1M TEAB using Vivaspin centrifugal concentrators (VS0413,
Sartorius, Epsom, UK) as per the manufacturer’s instructions (Figure 3b).
Protein digestion and iTRAQ labelling. Preparation of samples for
proteomics was as previously described.44
High pH reverse phase chromatography. iTRAQ-labelled samples
were reconstituted in 100ml of 0.1% ammonium hydroxide and pooled prior to
loading onto a 100 4.6 mm, 3 mm C18 HPLC column (Fortis, Cheshire, UK).
Peptides were eluted by addition of a linear 30min gradient up to 50% acetonitrile,
0.1% ammonium hydroxide with 70 15 s fractions collected from 4min. Fractions
were dried in a SpeedVac (ThermoFisher Scientific, Loughborough, UK) at 60 1C
and stored at  20 1C.
LC/MS/MS. Samples were reconstituted in 130ml of 0.1% Trifluoroacetic acid
(TFA), 2% acetonitrile. Half was loaded onto a trap column using a U3000 liquid
chromatography system (Dionex, Sunnyvale, CA, USA) and peptides fractionated
with a capillary RP C18 HPLC column (Acclaim PepMap C18, 3mM 100 A˚), flow
rate 0.8ml/min, 2–40% acetonitrile, 0.1% TFA. The flowthrough was spotted onto a
MALDI plate (AB SCIEX, Foster City, CA, USA) in 15 s fractions using an online
Probot (Dionex) with a-cyano-4-hydroxycinnamic acid mixing with eluent, final
concentration 1.25mg/ml. Mass spectrometry was on an AB SCIEX TOF/TOF
5800 (AB SCIEX, Framingham, MA, USA) using 1000 shots for MS. MS/MS was
applied to the top 27 precursors with a S/N of48 using 4000 laser shots, a 2-KV
acceleration voltage and air as collision gas.
Protein database searching and false discovery rate calcula-
tion. Proteins were identified using ProteinPilot v3.0 (AB Sciex) against the IPI
Human (v3.59) protein sequence database as described in.43 FDR determination
and protein quantification are described in detail in the Supplementary material
and follows a q-value-based statistical approach as previously described.15
Radiochemical synthesis of [18F]ML-10. A novel multi-step synthesis
of ML-10 was developed in-house (Kadirvel M, Brown G; manuscript submitted).
The radiochemical synthesis of di-tert-butyl ester of [18F]ML-10 was prepared by
Kryptofix) (Sigma-Aldrich, Gillingham, UK)-mediated nucleophilic fluorination of the
mesylate group of di-tert-butyl 2-methyl-2-(50-((methylsulfonyl)oxy)pentyl)malo-
nate. Finally, deprotection of di-tert-butyl ester of [18F]ML-10 by acid hydrolysis
gave [18F]ML-10. Isolation of pure [18F]ML-10 was achieved by semi-preparative
reverse phase HPLC. The radiochemical synthesis used the FX-FN platform (GE
Healthcare, Chalfont-St Giles, UK). The radiochemical yield (decay-corrected) of
[18F]ML-10 from nucleophilic [18F]fluoride was 26–31%, giving 4.54–5.79GBq of
product at the end of the radiosynthesis (EOS). The radiochemical purity was
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X99%, and the specific radioactivity was 25.3–29.2 GBqmol 1 (EOS). The total
radiosynthesis time was B80min.
PET imaging. Animals underwent dynamic baseline scanning when xenograft
size had reached B200–300mm3 for subcutaneous tumors. Animals were
anaesthetised with 1–2% Isoflurane, the tail vein was catheterised and they were
placed in the animal bed (Equipment Veterinaire Minerve, Esternay, France) and
transferred to a preclinical PET scanner (Inveon, Siemens, Malvern, PA, USA). At
the start of the acquisition, mice were injected with 30–70MBq of [18F]ML-10
(synthesised ‘in-house’ using published protocols41) intravenously (IV) via the tail
vein. List mode data were collected for 105min, in accordance with maximal
acquisition times advised.45 Anaesthesia was maintained during image acquisition
via a nose cone, with respiration and temperature monitored throughout using
appropriate systems. After imaging, animals were recovered in a warmed
chamber, randomized into treatment groups and rescanned at 24 h after induction
of revC3 with doxycycline. Immediately after the last scan, the tumors were
excised, weighed and half-fixed in 10% formalin, and half snap-frozen in liquid
nitrogen for western blot analysis.
Image reconstruction and data analysis. Before reconstruction, the
list-mode data were histogrammed with a span of 3 and maximum ring diffe-
rences of 79 into 3D sinograms with 21–33 time frames (5 60 s (s), 5 120 s,
5 300 s and 6 to 18 300 s) for image reconstruction. Images were
reconstructed using the 3D-OSEM/MAP algorithm (4 OSEM3D iterations and no
MAP iterations, with a requested resolution of 1.5 mm). ROIs were drawn manually
over tumor and a section of liver using Inveon Research Workplace software
(Siemens, Germany) and further normalization was performed using the injected
dose (from the dose calibrator) and animal weight to give a standardized uptake
value (SUV). SUVmean was calculated as the average over all voxels, with
normalized uptake values (NUV) calculated by dividing SUVmean from the tumor
by that from the liver contents.
Statistical tests. Unless otherwise stated, P-values are derived from
Student’s t-test.
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